SciClone Pharmaceuticals IPO Initiation: A Hard Sell
SciClone is pre-marketing a Hong Kong IPO to raise $500 million, according to press reports. Overall, on a fundamental basis, we are inclined to...
486 Views
China Biologic's Privatisation Redux
On Wednesday after market close, China Biologic Products (CBPO US) announced a surprising privatisation bid from a consortium for $120 per ADS. The...
500 Views
Para IV Winners and Losers - June 2018
This month’s Para IV developments suggest that there is likely to be benefit to Baxter International Inc (BAX US) on Premix Precedex (4mc/ml), Endo...
336 Views
China's Healthcare Reform Consolidates Drug Distribution and Cuts Manufacturer Margins
Rolling Out A “Two Invoices” System Nationwide:Although the announcement of a new policy to consolidate the distribution channels for both...
295 Views
Trump Health Effect: What Is Next for the Consumer Health Industry Under Trump's Leadership?
While the US consumer health industry will remain a strong centre for investment, development and technology innovation in 2017 and is expected to...
3.2k Views